News
![tafinlar_mekinist](https://pharmaphorum.com/wp-content/uploads/2022/06/tafinlar_mekinist-1.jpg)
Novartis bags FDA okay for BRAF-positive tumour combination
Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in t